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used to elicit participant-reported safety data 
in uncomplicated malaria clinical drug studies:  
a Delphi technique study
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Abstract 
Background: Eliciting adverse event (AE) and non-study medication data reports from clinical research participants 
is integral to evaluating drug safety. However, using different methods to question participants yields inconsistent 
results, compromising the interpretation, comparison and pooling of data across studies. This is particularly important 
given the widespread use of anti-malarials in vulnerable populations, and their increasing use in healthy, but at-risk 
individuals, as preventive treatment or to reduce malaria transmission.
Methods: Experienced and knowledgeable anti-malarial drug clinical researchers were invited to participate in a 
Delphi technique study, to facilitate consensus on what are considered optimal (relevant, important and feasible) 
methods, tools, and approaches for detecting participant-reported AE and non-study medication data in uncompli-
cated malaria treatment studies.
Results: Of 72 invited, 25, 16 and 10 panellists responded to the first, second and third rounds of the Delphi, respec-
tively. Overall, 68% (68/100) of all questioning items presented for rating achieved consensus. When asking general 
questions about health, panellists agreed on the utility of a question/concept about any change in health, taking care 
to ensure that such questions/concepts do not imply causality. Eighty-nine percent (39/44) of specific signs and symp-
toms questions were rated as optimal. For non-study medications, a general question and most structured questioning 
items were considered an optimal approach. The use of mobile phones, patient diaries, rating scales as well as openly 
engaging with participants to discuss concerns were also considered optimal complementary data-elicitation tools.
Conclusions: This study succeeded in reaching consensus within a section of the anti-malarial drug clinical research 
community about using a general question concept, and structured questions for eliciting data about AEs and non-
study medication reports. The concepts and items considered in this Delphi to be relevant, important and feasible 
should be further investigated for potential inclusion in a harmonized approach to collect participant-elicited anti-
malarial drug safety data. This, in turn, should improve understanding of anti-malarial drug safety.
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Background
As part of efforts to eradicate malaria and stem the devel-
opment of resistance to anti-malarial treatment, novel 
compounds or new molecular entities (NMEs) are being 
developed to meet the continued need for both the treat-
ment and prevention of malaria [1, 2]. Before these can 
be marketed for use in the general population, they must 
first be assessed in clinical trials to establish their effi-
cacy and safety profiles. Due to inherent limitations of 
clinical trials to fully assess safety, more studies are then 
conducted post-licensure to continue to build knowl-
edge about adverse drug effects (and effectiveness) in 
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real-world contexts and vulnerable populations excluded 
from clinical trials [3]. Pooling safety data collected dur-
ing numerous clinical studies facilitates the more accu-
rate definition of the nature and risk of adverse effects. 
This is especially important where the harm: benefit bal-
ance may be shifted when medicines are to be used in 
asymptomatic or uninfected people to prevent malaria 
or reduce malaria transmission. For instance, a relatively 
minor adverse drug reaction in a patient may be unac-
ceptable if the drug is introduced as a disease preven-
tive strategy in a healthy population, such as during mass 
drug administrations, when potentially more people with 
either contra-indicated or understudied conditions will 
be exposed [4–6].
Regulatory agencies recommend the method of col-
lecting safety data to be explicit in study reports because 
of its potential impact on the study results, and, further-
more, that methods should be standardized within drug 
development programmes [7]. However, they do not 
in general specify which methods to use. This compro-
mises the interpretation of individual studies and sub-
sequent systematic reviews or meta-analyses [8]. Drug 
safety and tolerability profiles are generated by gathering 
adverse event (AE) data which are then considered for 
any potential relationship to the study drug by consider-
ing other factors, including what is known about a partic-
ipant’s medical history and use of non-study medication. 
Objective AE assessments include medical examinations 
and laboratory tests, which are likely to be standardized 
within and between studies [9]. Studies also rely on sub-
jective AE reports that are obtained directly from trial 
participants by asking them about their health status over 
a defined period of time. The impact of the questioning 
(elicitation) method on safety data is considered to be 
an important issue that has not received enough atten-
tion [10, 11]. More structured questioning (such as with 
checklists or rating scales) increases the number of AEs 
reported compared to an open-ended or general enquiry 
[12, 13]. Proponents for a general enquiry believe this 
collects data which is more clinically meaningful even 
though it may be less sensitive [14]. An argument against 
the structured enquiry reflects concerns that it artificially 
increases the AE reporting rate as it may be suggestive, 
thereby biasing participant responses [15]. Structured 
methods may also be more time consuming and less fea-
sible to conduct in practice. Proponents of the structured 
enquiry, meanwhile, argue that this method is necessar-
ily more sensitive as it detects AE data which participants 
do not report spontaneously [16].
For malaria specifically, a previous study conducted by 
this study’s authors, provides evidence that when partici-
pants forgot an AE, or did not consider it significant or 
relevant when asked by general enquiry, a more specific 
enquiry prompted a report [12]. A subsequent survey 
of anti-malarial drug clinical researchers found that, for 
capturing AEs in intervention studies, most researchers 
used a combination of a general and structured enquiries 
(31%) or structured enquiry only (26%) with fewer using a 
general enquiry alone (18%) [17]. A minority of research-
ers incorporated tools involving pictures [18]. The elicita-
tion of previous and concomitant (non-study) medicine 
data reports are also important for assessing AEs for a 
potential relationship with a study drug. In the survey, 
most researchers reported using a general enquiry when 
asking questions about use of these with explicit refer-
ence to, for instance, “prescription only medication”, 
“over-the-counter medication”, “traditional medication”, 
“supplements” and “vaccinations”.
Following on from previous work in this area men-
tioned above, the aim of this research study was to seek 
consensus among a panel of anti-malarial drug clinical 
researchers about which methods they consider optimal 
(relevant, important and feasible) for eliciting AE and 
non-study medication data from participants in uncom-
plicated malaria drug studies. This is expected to contrib-
ute to the development of a harmonized approach that 
may, in turn, facilitate more accurate interpretation or 
pooling of participant-elicited safety data from multiple 
studies.
Methods
The Delphi
A Delphi technique study design was selected as its aim is 
to achieve consensus on a particular topic. This method 
was developed in the 1950s by the RAND Corporation 
and involves soliciting opinions from a panel of knowl-
edgeable individuals with relevant experience and exper-
tise in a particular area. Successive rounds of questioning 
about a topic are conducted after individual results from 
the previous round are reported back to the group for 
consideration [19]. Panellists remain anonymous to each 
other to avoid domination by any one individual and to 
allow for freedom of expression without reservation or 
fear of condemnation or ridicule [20–22].
Questionnaires (Additional file  1) to elicit panel-
list opinions were designed and pilot tested before they 
were administered online through SurveyGizmo® so that 
panellists did not have to be in the same physical loca-
tion, and could complete the questionnaire at a conveni-
ent time [23, 24]. In the first round, they were presented 
with a summary of relevant literature, including previous 
work by the authors, and were asked open-ended ques-
tions about what they considered the optimal method(s), 
concept(s) and/or approach(es) for asking study partici-
pants (or caregivers) to collect subjective AE and non-
study medication data (Additional file  2). Space was 
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provided for free-text comments and suggestions of fur-
ther methods or considerations pertinent to this complex 
field.
Specific phrases suggested by participants in round 
one were then categorized into questioning concepts 
for rating in subsequent rounds as regards their rele-
vance, importance and feasibility; i.e. to be optimal they 
should fulfil all three criteria, as all would be appropriate 
for malaria clinical research for detecting participant-
reported AEs and non-study medication. Comments, 
suggestions and further methods were paraphrased 
into short descriptions and panellists were advised that 
the wording of questions or items themselves were only 
examples of possible phrases/words; exact terminology 
may be context-specific or adapted for ensuring local 
understanding of the question by study participants. For 
instance, they were asked to rate the following types of 
general question concepts (with examples) that may be 
posed to participants in an anti-malarial study: “Gen-
eral question about feeling (e.g. ‘How have you [has 
your child] been feeling?)”. Similarly, an example of a 
structured approach was “Questions about body parts, 
systems or functions (e.g. ‘Have you experienced a prob-
lem with your head, chest, breathing?’)”. This approach 
was applied throughout the Delphi, where appropri-
ate. Rating was achieved using a nine-point Likert scale 
with options ranging from ‘strongly agree’ to ‘strongly 
disagree’.
In the third and final round, each panellist was sent 
descriptive statistics summarising all responses from 
round two and their individual responses. For items that 
had not achieved consensus they were asked whether or 
not they wished to change their opinion/rating in light 
of the summary information from all panellists [25]. The 
time lapse between rounds of the Delphi ranged between 
3 and 6 months.
The definition of consensus in Delphi technique studies 
varies from study to study. For this study, each compo-
nent was considered to have reached consensus when at 
least 70% of panellists selecting options within a three-
point region indicating that most panellists disagree 
(score 1–3), are uncertain (score 4–6), or agree (score 
7–9) that a given item is optimal [21, 25, 26]. Individual 
items were not mutually exclusive – for example, pan-
ellists could recommend both a general enquiry and a 
structured enquiry method.
Study population and sampling
Participation was limited to individuals with experience 
and knowledge of clinical anti-malarial drug studies to 
ensure they could contribute constructively to the pro-
cess [20, 24]. All panellists needed to meet one or more of 
the following criteria:
(i) A clinical researcher who has been responsible for a 
clinical trial/study where AE and/or non-study medica-
tion data was collected as part of the protocol.
(ii) An individual who has been responsible for the 
selection, design, review or testing of tools to collect clin-
ical trial/study AE and/or non-study medication data.
(iii) An individual who has had direct involvement in 
the elicitation and recording of AE and non-study medi-
cation data from participants within malaria clinical 
trials/studies.
(iv) A representative of a regulatory authority responsi-
ble for reviewing clinical trial/study data, whether pre- or 
post-marketing.
(v) A representative of a sponsor who has funded and/
or conducted malaria clinical trials.
Sampling was purposive to ensure that those who 
were invited met the inclusion criteria, and was largely 
from those who had taken part in the previous sur-
vey [17]. Individuals from organisations well known for 
researching or developing anti-malarial drugs were also 
approached. Self-selection by those invited ultimately 
determined who responded and participated in each of 
the rounds.
Sample size
The sample size of a Delphi panel is not a statistically-
bound parameter and good results can still be obtained 
using a comparatively small group of even heterogeneous 
experts [27]. Considering the highly specific inclusion 
criteria and anticipated attrition at each round, there was 
no limit set to the number who could take part, and no 
sample size calculation was done.
Data management and analysis
Responses were downloaded from SurveyGizmo® and 
analysed using Microsoft Excel®. The two main sec-
tions, Section A (AEs) and Section B (non-study medi-
cines) were each further sub-divided to include three 
sub-sections on general questioning items, structured 
question items, and pictorial and/or physical question-
ing tool items. Consensus was assessed individually per 
item included in the questionnaires, and overall per 
sub-section.
Results
A total of seventy-two researchers were invited to partic-
ipate, of whom 25 (35%) completed round one. In round 
two all panellists who had completed round one were 
re-invited. Of these, 16/25 (64%) responded, with fifteen 
fully completing the round and one panellist partially 
completing the questionnaire. In the final round, all who 
had fully completed round two were invited and 10/15 
(67%) responded.
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Study participants
The study population was comprised mostly of those 
who met at least two of the inclusion criteria. Of the 25 
participants in round one, 18 (72%) had been responsi-
ble for the selection, design, review and/or testing of 
relevant tools, 16 (64%) had five or more years of experi-
ence in malaria clinical studies and a further 3 (12%) had 
1–5 years of experience. Panellists came from seventeen 
countries, with over half (14/25) coming from malaria 
endemic countries. Most countries represented had one 
panellist [Australia, Bangladesh, Burkina Faso, Denmark, 
Gabon, The Gambia, Kenya, Malawi, Mali, Nigeria, Tan-
zania, Uganda, the United Kingdom] but some had more 
than one [USA (2), Zambia (2), Ghana (2) and Belgium 
(3)].
Assessment of consensus
The percentage of all items reaching consensus overall 
rose from 24% in round two to 68% in round 3 (Table 1). 
The majority of items reaching consensus in round two 
were structured questions about signs and symptoms 
and non-study medication. See Table  2 for a summary 
of consensus status for individual questioning items as 
described below.
Asking participants about AEs
Panellists agreed that an explicit question about change 
in health (e.g. ‘Have you observed any change or new 
complaint since your last visit/in the past x days [trial-
specific time scale]?’) was optimal for asking about AEs 
during malaria clinical trials. They also agreed that a 
general question implying causality should be avoided 
(e.g. ‘Did your child experience any side effect from the 
drug since your last visit/in the past x days [trial-specific 
time scale]?’). Consensus could not be reached on items 
pertaining to the general questions asking about how 
a study participant was feeling (e.g. ‘How have you [has 
your child] been feeling since your last visit/in the past 
x days [trial-specific time scale]?’), whether they had had 
past adverse reactions to treatments (e.g. ‘Have you ever 
reacted badly to a drug or vaccine?’) or how they rated 
any change in health (e.g. ‘How do you rate your state of 
health after taking the study medicine?’).
Few specific questions about body parts, systems or 
functions achieved consensus about whether or not they 
were optimal in structured questioning (3 of 11 possible 
items). However, 90 percent (40/44) of specific signs and 
symptoms achieved consensus; 39/40 of these were rated 
as being optimal with one (oculogyric crisis) recom-
mended as not optimal. The suggestion by one panellist 
of oculogyric crisis in round one, a complex medical term 
that would not be understandable to study participants, 
was likely to reflect a misunderstanding of the concept of 
or terms suitable for eliciting participant reported AEs. 
Consensus was also reached for showing study partici-
pants pictures or photos of ‘mucous membrane blisters’ 
and ‘skin rash’ to elicit reports, with no other body parts 
being recommended in this format. Panellists also agreed 
that collecting AE reports using mobile phones or patient 
diaries, using an archive of visual analogue scales or digi-
tal photographs of AEs and “openly engaging participants 
to discuss any concerns they have” were all ideas that 
should be considered.
Asking participants about non‑study medication use
Panellists agreed that asking a general question about the 
use of non-study medications (e.g. ‘Have you taken any 
medications since your last visit/in the past x days [trial-
specific time scale]?’) was optimal, as were, in addition, 
all but one of the eleven structured questioning items on 
Table 1 Overall number of questions reaching consensus by sub-section
Elicitation methods Number of items Items reaching consensus
Round 2 Round 3 Total
Adverse events
General questions 5 1 1 2 (40%)
Structured questions about body parts, systems or function 11 0 3 3 (27%)
Structured questions about signs and symptoms 44 16 24 40 (91%)
Pictorial questioning tools 14 0 2 2 (14%)
Other (see Table 2 for details) 8 1 4 5 (63%)
Non-study medication
General questions 1 1 N/A 1 (100%)
Structured questions 11 5 5 10 (91%)
Pictorial and/or other physical tools 5 0 4 4 (80%)
Other 1 0 1 1 (100%)
Total 100 24 44 68 (68%)
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Table 2 Summary of consensus status for individual questioning items
Items rated Consensus status
Section A
General questions about AEs Round 2 Round 3
 Explicit question about change in health (e.g. ‘Have you observed any change or  
new complaint since your last visit/in the past x days [trial-specific time scale]?’)
Optimal
 Question implying causality (e.g. ‘Did your child experience any side effect from the  
drug since your last visit/in the past x days [trial-specific time scale]?’)
Not optimal
 General question about feeling (e.g. ‘How have you [has your child] been feeling  
since your last visit/in the past x days [trial-specific time scale]?)
No consensus
 General question about past adverse reactions to treatments  
(e.g. ‘Have you ever reacted badly to a drug or vaccine’)
No consensus
 General question about rating any change in health  
(e.g. ‘How do you rate your state of health after taking the study medicine?’)
No consensus
Structured questions about body parts, systems or function  
(e.g. ‘Have you experienced a problem with your head, chest, breathing….?’  
or ‘Have you experienced fever, headache, rash….?’)
Round 2 Round 3
Nose Optimal
Lungs/breathing Optimal
Head Optimal
Ears No consensus
Throat No consensus
Eyes No consensus
Chest No consensus
Heart No consensus
Lymphatic system No consensus
Nervous system No consensus
Tiredness/fatigue/weakness/lethargy Optimal
Muscle pain Optimal
Joint pain Optimal
Abdominal pain Optimal
Mood/behavioural change Optimal
Allergic skin rash (e.g. some forms of urticaria) Optimal
Skin abnormalities Optimal
Dizziness Optimal
Vision/sight problem Optimal
Change in urine colour Optimal
Palpitations Optimal
Confusion Optimal
Jaundice/icterus Optimal
Oculogyric crisis Not optimal
Photosensitivity (sensitivity to light) Optimal
Spontaneous bleeding Optimal
Constipation Optimal
Blisters (on skin or mucous membrane) Optimal
Hallucinations Optimal
Headache Optimal
Fever Optimal
Cough Optimal
Loss of appetite Optimal
Vomiting Optimal
Nausea Optimal
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Table 2 continued
Structured questions about body parts, systems or function  
(e.g. ‘Have you experienced a problem with your head, chest, breathing….?’  
or ‘Have you experienced fever, headache, rash….?’)
Round 2 Round 3
Diarrhoea Optimal
Itching (no rash) Optimal
Peeling skin Optimal
Tinnitus (ringing in the ears)/hearing problem Optimal
Sleep disturbance/nightmares Optimal
Involuntary movements (e.g. rigors/convulsions/seizures) Optimal
Wheezing/difficulty breathing Optimal
Non-allergic skin rash (e.g. scabies) No consensus
Posturing No consensus
Pallor No consensus
Change in walking (gait disturbance) No consensus
In infants
Eating/drinking/feeding less than normal Optimal
Irritable Optimal
Abnormal sucking, if breastfed Optimal
Crying more than normal Optimal
Difficult to arouse Optimal
In pregnant women
Baby movements less than normal Optimal
Vaginal bleeding Optimal
Increased uterine contractions, more than normal Optimal
Pictorial questioning tools about AEs Round 2 Round 3
Using photographs, drawings or pictures of the following signs and symptoms
Mucous membrane blisters Optimal
Skin rash Optimal
Headache No consensus
Fever No consensus
Loss of appetite No consensus
Diarrhoea No consensus
Jaundice/icterus No consensus
Joint pain No consensus
Pruritus No consensus
Using photographs, drawings or pictures of the following body parts
Respiratory system No consensus
Gastrointestinal tract No consensus
Central nervous system No consensus
Skin No consensus
Other Round 2 Round 3
Whole body outline No consensus
Collecting AE reports using mobile phones Optimal
Collecting AE reports using patient diaries Optimal
Using an archive of visual analogue scales from day 0 throughout all the follow-ups to measure 
potential AEs and any change in the occurrence of these events
Optimal
Openly engaging participants to discuss any concerns they have Optimal
Keeping an archive of digital photographs of AEs Optimal
Collecting AE reports using group discussions No consensus
Using flip charts, with a picture on one side for the participant and a written question for the 
investigator on the reverse side (to reduce investigator variability)
No consensus
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source of medicines, treatment class or specified indica-
tions. The one item which failed to achieve consensus 
was whether or not items about “vitamins” as a treat-
ment class were optimal. Panellists could also not agree 
whether the option of showing samples of commonly 
used herbs or traditional remedies specific to the study 
context was optimal. However, they did agree that par-
ticipants should be asked about individual treatments by 
name according to what is known to be locally relevant.
Discussion
This study provides an important contribution to 
the methodological field of developing harmonized 
approaches to eliciting data about AEs and use of 
non-study medication within uncomplicated malaria 
drug studies. Consensus was achieved among panel-
lists that a general question is optimal for capturing 
subjective AE reports; specifically that such an enquiry 
is best phrased to elicit information about a change in 
the participant’s health but not imply that participants 
should only report issues which they perceive as caused 
by the study drug. This is consistent with the tenet of 
drug safety assessment that AEs are captured regard-
less of any potential attribution to the drug in clini-
cal trials [28]. While investigators have been aware of 
this for decades, there has been little attention to how 
questions are designed to help ensure that study par-
ticipants report any health-related concerns but do not 
Table 2 continued
Other Round 2 Round 3
Using video footage on smartphones or tablets to show how some AEs which are difficult to 
depict on still images may manifest e.g. seizure activity
No consensus
Section B
General questions about previous or concomitant medication (non‑study druG) Round 2 Round 3
General questions about the use of non-study medications (e.g. ‘Have you taken any medications 
since your last visit/in the past x days [trial-specific time scale]?’).
Optimal
Structured questions about previous or concomitant medication (non‑study drug) Round 2 Round 3
Questions about the source of medicines (e.g. ‘Have you received any medication from a traditional 
healer since you were last seen here?’):
Medicine obtained from another health facility Optimal
Medicine obtained from a drug shop, pharmacy, chemical seller, the market (or equivalent) Optimal
Medicine obtained from a traditional healer, informal doctor (or equivalent) Optimal
Medicines already available in the home (from previous treatment courses). Optimal
Medicines obtained from family and/or friends Optimal
Collecting and using naturally occurring herbs/remedies Optimal
Structured questions about treatment class or specified indication
Analgesics/anti-inflammatory drug Optimal
Antibiotics Optimal
Antihistamines Optimal
Anti-malarial Optimal
Vitamins No consensus
Other Round 2 Round 3
Asking about individual treatments by name according to what is known to be locally relevant Optimal
Pictorial and/or other physical tools to question about previous  
or concomitant medication (non‑study druG)
Round 2 Round 3
Showing photographs or drawings of commonly used drugs or drug packets Optimal
Showing samples of commonly used drugs or drug packets Optimal
Showing photographs or drawings of commonly used herbs/traditional remedies Optimal
Asking participants to bring any non-study medication they may have taken before and/or dur-
ing the trial/study to scheduled visits for a physical inspection
Optimal
Showing samples of commonly used herbs/traditional remedies No consensus
Summary of consensus status for individual questioning items rated for relevance, importance and feasibility for asking participants in uncomplicated malaria clinical 
trials/studies about adverse events and non-study medication
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unwittingly filter information. The concept of an ideal 
phrase for general questions postulated through this 
Delphi study should prove useful to guide trial teams 
in designing their AE elicitation methods, and could be 
used to achieve consistency within and between trials. 
There was also agreement, however, between the Delphi 
panellists about optimal structured questions to elicit 
AE reports, presenting various signs and symptoms for 
participants to consider. General and structured ques-
tions are therefore not necessarily mutually exclusive. 
As shown by previous studies, a structured approach is 
likely to increase the sensitivity of detecting AEs, some 
of which may have been forgotten or not considered rel-
evant or important by participants [11, 12]. While this 
may increase the workload for trial staff, using a list 
will ensure standard practice within and between study 
teams. The list developed through this Delphi study will 
require further refinement as there was overlap between 
some items identified as optimal (e.g. several skin condi-
tions were considered for inclusion in a questioning tool 
individually and also as a general term). Moreover, the 
recommendation for using digital photos of AEs (e.g. of 
‘mucous membrane blisters’), which could complement a 
structured approach, needs to be explored in detail.
A higher degree of consensus was achieved for ques-
tions that elicit non-study medication reports compared 
to AE reports. There may be less controversy about 
whether different questioning methods impact on the 
data for non-study medication exposures than AEs, with 
a smaller potential for these questions biasing responses. 
These data are inherently different - AEs being subjective 
experiences, while taking a non-study medication a more 
concrete occurrence. Using structured questioning tools 
in conjunction with general questioning, and giving defi-
nitions and examples of individual treatments by name 
and treatment class according to what is relevant in the 
local context, will help ensure that trial participants do 
not inadvertently omit information based on their own 
understanding of what constitutes a medicine. Asking 
about the source of medicines could also be particularly 
important in communities where the use of alternative 
and/or traditional medicines or remedies is widespread 
and common practice, as previous work has shown that 
there may be reluctance to volunteer such traditional 
therapies (12). In some instances the indication for which 
the non-study medication was taken could identify an 
unreported AE which may have resulted from taking the 
study medication [29]. There should be discussion within 
a research team, therefore, as to how to encourage partici-
pants to feel comfortable enough to report items without 
fear of negative consequences, as reflected by the Delphi 
panellists’ recommendation for “open engagement with 
participants to discuss any concerns they may have”. This 
is a facet of questioning other than structure, phraseology 
and content that should not be dismissed as obvious or 
trivial. As such, there is a need for reflection on the wider 
literature relating to health communications, including 
work already conducted with clinical research staff who 
question malaria patients about their health [18, 30, 31]. 
Similar to eliciting non-study medicine reports, questions 
about health should reflect local understandings of illness; 
simple translations of a particular tool would likely not be 
sufficient. Further work is required to aid similar inter-
pretation of items in different settings. Should staff par-
aphrase or further explain certain concepts, they should 
understand the rationale for asking particular types of 
questions to capture relevant data and achieve the trial’s 
safety objectives, and the potential implications of subtle 
changes in wording on reports elicited.
Thus, the details of optimal permutations not resolved 
during the Delphi and refinement of this basket of poten-
tial options, should now be taken forward for further 
discussions within the anti-malarial drug research com-
munity. This could be done at the time of international 
meetings with those interested malaria researchers, ide-
ally joined by health communications specialists and 
those who have experienced malaria as a patient.
Limitations
There is clearly more work needed to fully explore the 
potential for harmonization of safety data elicitation 
methods. The Delphi was concluded before consensus on 
all items could be established. While consensus for those 
unresolved items may have been achieved in further 
rounds, this is not necessarily the case and the lack of 
consensus on these items may indicate that those items 
are not widely considered optimal. This may reflect the 
complexity of the topic, including the composite concept 
used for the definition of ‘optimal’, which is likely further 
confounded by the attrition rate of panellists, the time-
lapse between rounds, and the highly varied contexts in 
which the panellists conduct research; although there is 
no consensus, for instance, a response rate of 70% has 
been suggested as necessary to maintain rigour, and this 
Delphi achieved 64% and 67% in rounds 2 and 3 respec-
tively [32]. However, efforts were made to reduce attri-
tion and the time between rounds, including multiple 
email reminders. There was indication of some misun-
derstanding of the concept of “participant-reported” AEs 
(the inclusion of oculogyric crisis).
Recommendations
This online Delphi technique study showed that it is 
possible to engage multiple researchers from around 
the world to collaborate on working towards the devel-
opment of harmonized approaches for questioning 
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participants about AE and non-study medication data. 
The results should now be taken forward for further 
refinement and pilot testing of harmonized tools. These 
will require deliberation about optimal permutations of 
items and the potential use of mobile phones, diaries and 
rating scales.
Conclusion
The development of an accurate understanding of a 
drug’s safety profile is essential for all medicines, espe-
cially for those anti-malarials which are distributed 
widely to vulnerable at-risk populations, including unin-
fected persons as part of prevention strategies. The 
participant-reported data that contribute to drug safety 
assessments can be influenced by the elicitation methods 
used to collect this information. A harmonized approach 
for collecting AE and non-study medication data during 
uncomplicated malaria clinical studies could contribute 
to improving the interpretation, comparison and pool-
ing of data from different studies. Such a harmonized 
approach could incorporate items that achieved consen-
sus within this Delphi technique study. For eliciting AEs 
these included: a particular general question concept, 
structured questions about certain symptoms, use of 
mobile phones, diaries, visual analogue scales and pho-
tographs of symptoms, and openly engaging with partici-
pants. For eliciting non-study medication reports, these 
include: a general question concept; structured questions 
about medicine sources, treatment classes and indica-
tions, and asking about local treatments by name; show-
ing photographs, drawings or samples of commonly used 
treatments, and asking participants to bring non-study 
medication to visits. Further discussion is needed within 
the malaria research community as to how to refine these 
options for implementation in clinical trials.
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